Core Viewpoint - The company anticipates a recovery in the domestic medical equipment market starting from Q4 2024, with significant growth in procurement amounts in the first four months of the year, leading to a positive revenue trend for the year [1] Group 1: Market Environment and Performance - The company held its annual shareholder meeting and investor communication session, discussing market conditions, product layout, and technological innovation [1] - The procurement amount for medical equipment in hospitals has significantly increased, indicating a potential rapid recovery in the industry [1] - The company expects its revenue to return to a growth trend, with hospital procurement for the year projected to outperform last year [1] Group 2: Product Development and Innovation - The company plans to launch several new products in 2025, including the ultrasound 80 platform, HD-580 series endoscopes, and IVUS for cardiovascular intervention, which will form the basis for revenue growth [2] - The HD-650 endoscope, featuring super-resolution imaging and 4K resolution, is set to be launched in the second half of 2025, marking a significant advancement in the company's endoscope product line [2] - The minimally invasive surgical product line is expected to see over 100% growth in Q1 2025, with substantial year-on-year revenue increases anticipated for the full year [2] Group 3: AI Technology Integration - The company is focusing on AI technology as a key development direction for future medical devices, implementing a "device + AI" strategy [2] - Significant AI achievements have been made in the ultrasound and endoscope sectors, including the first domestic AI medical device certification for prenatal ultrasound screening [3] - The company has developed independent AI software for endoscopy, enhancing real-time quality control capabilities [3]

Group 1 - The company held its 2024 annual shareholder meeting and investor communication session, discussing market environment, product layout, and technological innovation [1] - The chairman indicated that domestic medical equipment procurement is expected to recover rapidly starting from Q4 2024, with significant growth in procurement amounts in the first four months of the year [1] - The company has completed its product line layout across ultrasound, digestive and respiratory endoscopy, minimally invasive surgery, and cardiovascular intervention, establishing a long-term product matrix [1] Group 2 - The company reported a noticeable recovery in hospital procurement since Q1 2025, with a significant increase in successful bids, outperforming the industry average [2] - The company anticipates a return to revenue growth in 2025, driven by the recovery of terminal procurement and the implementation of medical equipment update policies [2] - The company maintains a high R&D investment ratio to ensure the introduction of advanced products, which supports high gross margins [2] Group 3 - 2025 is expected to be a significant year for new product launches, including ultrasound 80 platform, HD-580 series endoscopes, and IVUS for cardiovascular intervention [3] - The HD-650 endoscope, featuring super-resolution imaging and 4K resolution, is set to launch in the second half of the year, marking a technological advancement in the industry [3] - The company is focused on controlling team expansion and managing expenses to ensure profit output [3] Group 4 - The company has been advancing its multi-product line strategy, leveraging its technological advantages in ultrasound and endoscopy [4] - The minimally invasive surgery product line achieved a 30% year-on-year revenue growth in 2024, with Q1 2025 growth exceeding 100% [4] - The cardiovascular intervention product line saw a threefold increase in revenue in 2024, with ongoing product launches enhancing competitive strength [4] Group 5 - The company emphasizes the importance of AI technology in the future of medical devices and is investing heavily in AI applications [5] - The company has achieved significant AI technology milestones in ultrasound and endoscopy, including the first domestic AI medical device certification for prenatal ultrasound screening [5] - AI software has been developed for endoscopy, enhancing quality control and detection rates [5] Group 6 - Market expectations indicate strong demand for medical equipment procurement in 2025, potentially exceeding 100 billion yuan, with an accelerating pace of equipment updates [6] - The company, as a leading player in high-end products and technology, is well-positioned to capitalize on new product launches and strengthen its core competitiveness [6] - The company is expected to experience a robust recovery in performance and expand its market share globally [6]